ABSL-3 (Animal Biosafety Level 3) Lab Global Market Opportunities And Strategies To 2035

ABSL-3 (Animal Biosafety Level 3) Lab Services Market Definition

Animal biosafety level 3 (ABSL-3) lab services are specialized research and testing services conducted in high-containment laboratory facilities designed for work with animals infected with pathogens that can cause serious or potentially lethal diseases via inhalation. These labs operate under strict biosafety, biosecurity, and containment protocols. The primary purpose of ABSL-3 lab services is to safely support in vivo research on high-risk infectious agents while protecting personnel, the environment, and the public. The ABSL-3 lab services market consists of sales by entities (organizations, sole traders and partnerships) of ABSL-3 lab services utilize containment systems, engineering controls, and operating procedures that protect laboratory personnel, the environment, and surrounding communities from exposure to hazardous pathogens. ABSL‑3 lab services are used by researchers, scientists, and organizations involved in studying diseases, developing therapeutics, evaluating vaccines, and understanding pathogen behavior in animal models. They are essential at stages of preclinical research that involve infectious agents requiring stringent biosafety practices, complementing lower‑containment (ABSL‑1 and ABSL‑2) services and substituting for facilities that lack high‑containment capabilities.

ABSL-3 (Animal Biosafety Level 3) Lab Services Market Segmentation

The ABSL-3 lab services market is segmented by disease area, by pathogen types, by application, by species, by service types and by end user.

By Disease Area –
The ABSL-3 lab services market is segmented by disease area into:

• a) Respiratory infections
• b) Viral infections
• c) Other disease areas

The respiratory infections market was the largest segment of the ABSL-3 lab services market segmented by disease area, accounting for 45.8% or $242.9 million of the total in 2025. Going forward, the viral infections segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by disease area, at a CAGR of 9.4% during 2025-2030.

By Pathogen Types –
The ABSL-3 lab services market is segmented by pathogen types into:

• a) Viruses
• b) Bacteria
• c) Fungi
• d) Other Pathogen Types

The bacteria was the largest segment of the ABSL-3 lab services market segmented by pathogen types, accounting for 54.0% or $286.0 million of the total in 2025. Going forward, the viruses segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by pathogen types, at a CAGR of 9.5% during 2025-2030.

By Application –
The ABSL-3 lab services market is segmented by application into:

1. a) Antiviral Research And Development (R&D)
2. b) Vaccine Efficacy
3. c) Transmission
4. d) Other Applications

The antiviral research and development (R&D), market was the largest segment of the ABSL-3 lab services market segmented by applications, accounting for 35.6% or $188.8 million of the total in 2025. Going forward, the vaccine efficacy segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by applications, at a CAGR of 8.6% during 2025-2030.

By Species –
The ABSL-3 lab services market is segmented by species into:

• a) Rodent
• b) Non-Human Primate (NHP)
• c) Other Species

The rodent market was the largest segment of the ABSL-3 lab services market segmented by species, accounting for 52.6% or $279.0 million of the total in 2025. Going forward, the other species segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by species, at a CAGR of 8.7% during 2025-2030.

By Service Types –
The ABSL-3 lab services market is segmented by service types into:

• a) Efficacy Studies
• b) Pharmacokinetics/Pharmacodynamics (PK/PD) Studies
• c) Investigational New Drug (IND)–Enabling Packages
• d) Supporting Assays
• e) Other Service Types

The efficacy studies market was the largest segment of the ABSL-3 lab services market segmented by service types, accounting for 33.8% or $179.0 million of the total in 2025. Going forward, the investigational new drug (IND)–enabling packages segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by service types, at a CAGR of 8.8% during 2025-2030.

By End-User –
The ABSL-3 lab services market is segmented by end-user into:

• a) Pharmaceutical And Biotech Companies
• b) Contract Research Organizations (CROs)
• c) Academic And Research Institutions
• d) Not-For-Profit Research Organizations
• e) Governmental Institutes And Public Health Agencies
• f) Defense/Military
• g) Other End Users

The pharmaceutical and biotech companies market was the largest segment of the ABSL-3 lab services market segmented by end user, accounting for 43.9% or $232.9 million of the total in 2025. Going forward, the academic and research institutions segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by end user, at a CAGR of 8.4% during 2025-2030.

By Geography - The ABSL-3 lab services market is segmented by geography into:

o Asia Pacific
• China
• India
• Japan
• Australia
• Indonesia
• South Korea
o North America
• USA
o Europe

• France
• Germany
• UK
• Italy
• Spain
• Russia
o Rest Of The World

ABSL-3 (Animal Biosafety Level 3) Lab Services Market Competitive Landscape

Major Competitors are:

University of Pennsylvania (Jurado Lab)

Boston University

Constellation Brands Inc.

Carlsberg Breweries AS

Molson Coors Brewing Company

Other Competitors Include:

Kirin Holdings Co. Ltd.

Diageo plc

Bacardi Limited

Sapporo Breweries Ltd.

The Boston Beer Company Inc.

Australian Centre for Disease Preparedness (ACDP)

Elizabeth Macarthur Agricultural Institute (EMAI)

WuXi AppTec

JOINN Laboratories

YEBIO Bioengineering

Harbin Veterinary Research Institute (HVRI, CAAS)

Institute of Microbiology, Chinese Academy of Sciences (IMCAS)

Institute of Life Sciences (ILS), Bhubaneswar

Indian Veterinary Research Institute (IVRI)

Biovet Pvt. Ltd.

Biosafe Lab India Pvt. Ltd.

National Research and Innovation Agency (BRIN)

National Institute of Animal Health (NIAH)

Institute of Medical Science, University of Tokyo (IMSUT)

Woojung Bio

International Vaccine Institute (IVI, Seoul)

Jeonbuk National University

Korea Research Institute of Bioscience and Biotechnology (KRIBB)

IMeBIO Laboratories

Czech Centre for Phenogenomics

Helmholtz Munich

VetBioNet

MUNI SCI

Labover

Charles River Laboratories

Friedrich-Loeffler-Institut (FLI)

University of Padua

VISAVET

INIA-CISA (Animal Health Research Centre)

IRTA CReSA (Animal Health Research Center)

ISGlobal

Moredun Research Institute

University of South Florida (USF Health)

University of California (UC)

University of Minnesota

University of South Carolina

Southern Research

Texas Biomedical Research Institute (Texas Biomed)

Tulane University

Jurado Lab

SoBran, Inc.

BIOQUAL, Inc.

Illinois Institute of Technology Research Institute (IITRI)

Lovelace Biomedical

TICRO Bioservices

ABSL-3 (Animal Biosafety Level 3) Lab Services Market Drivers

The key drivers of the ABSL-3 lab services market include: Rising Incidence Of Airborne And High-Risk Infectious Diseases Rising incidence of airborne and high-risk infectious diseases is expected to be a key driver of growth for the ABSL-3 lab services market during the forecast period. The growing frequency of outbreaks involving airborne and highly transmissible pathogens has intensified the need for controlled animal-based research under enhanced biosafety conditions. Many of these pathogens pose severe risks to human health, requiring strict containment during in-vivo experimentation. Researchers increasingly rely on specialized environments to safely study transmission dynamics, pathogenesis, and immune responses. These studies support the development of vaccines, antivirals, and public health countermeasures. Increased global travel and urbanization have further amplified exposure risks, reinforcing sustained research activity in this area. The Rising incidence of airborne and high-risk infectious diseases growth contribution during the forecast period in 2025 is 8.2%.

ABSL-3 (Animal Biosafety Level 3) Lab Services Market Restraints

The key restraints on the ABSL-3 lab services market include: High Ongoing Operational And Maintenance Costs High ongoing operational and maintenance costs are restricting the growth of the ABSL-3 lab services market during the forecast period. High-containment animal facilities require continuous investment in specialized infrastructure such as advanced heating, ventilation, and air conditioning (HVAC) systems, HEPA filtration, pressure monitoring, and decontamination equipment to maintain biosafety standards. These systems operate around the clock and demand frequent validation, calibration, and maintenance to remain compliant. In addition, facilities must employ highly trained biosafety, veterinary, and technical staff, increasing labor costs. Regular regulatory inspections, certification renewals, and emergency preparedness drills further add to operational expenses. Together, these ongoing cost pressures limit scalability and constrain wider adoption of such specialized research capabilities.Growth affected by the high ongoing operational and maintenance during the forecast period in 2025 is -2.0%.

ABSL-3 (Animal Biosafety Level 3) Lab Services Market Trends

Major trends shaping the ABSL-3 lab services market include: Focus on Expanding Specialized High-Containment Animal Research Capabilities Companies operating in the ABSL-3 lab services market are focusing on expanding specialized high-containment animal research capabilities, particularly for non-human primate studies that support advanced vaccine and therapeutic development. They are investing in trained biosafety personnel, compliant in vivo infrastructure, and complex animal handling expertise to meet growing demand for translational research, enabling safe and efficient preclinical testing while adhering to strict regulatory and biosafety standards. For instance, in November 2025, NEIKER, a Spain-based public agricultural research and development center, begun a full renovation of its Biosafety Level 3 (BSL 3 / NCB3) animal health facilities to modernize and expand its high containment labs for working with dangerous pathogens that require strict biocontainment. NEIKER is carrying out a complete refurbishment of its Level 3 Biological Containment building (NCB3), which is used for major research lines in animal health. Expanding the facility’s floor area from about 673 m² to 853 m² (later reports note the renovated area at around 900 m² after adjustments). Restructuring the layout to create five independent laboratories instead of one open area, allowing different internal and external research groups to work simultaneously. Upgrading the animal experimentation area by separating small animal models (mice, guinea pigs, rabbits) from larger animal models, in line with current regulations and research needs. Next-Generation Decentralized Biosafety Networks For National Disease Preparedness Companies operating in the ABSL-3 lab services market are focusing on scaling infrastructure through multi-site expansion and partnerships with public institutions to improve geographic coverage and access to certified containment facilities. This approach supports decentralized testing, faster turnaround times, and participation in large government-funded biosafety programs. For instance, in March 2025, the Ministry of Health and Family Welfare, Government of India, approved and launched a nationwide network of bio-safety laboratories, including 11 new BSL-3 containment facilities as part of the “Setting up of a Nationwide Network of Laboratories for Managing Epidemics and National Calamities” initiative. These approvals, which cover high-containment labs across government research bodies and institutions, expand infrastructure for high-risk pathogen research and strengthen capacity for infectious disease diagnostics and studies. The scheme also includes support for multiple BSL-2 facilities and bolsters regional research hubs under central funding. By formalizing this infrastructure network, India enhances access to certified containment labs and reduces dependence on a small number of centralized facilities. This expansion supports broader biosafety and high-containment research capabilities for public health preparedness.

Opportunities And Recommendations In The ABSL-3 (Animal Biosafety Level 3) Lab Services Market

Opportunities – The top opportunities in the ABSL-3 lab services market segmented by disease area will arise in the respiratory infections segment, which will gain $104.8 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by pathogen types will arise in the bacteria segment, which will gain $127.6 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by applications will arise in the vaccine efficacy segment, which will gain $94.6 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by species will arise in the rodent segment, which will gain $132.5 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by species will arise in the efficacy studies segment, which will gain $87.6 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by species will arise in the pharmaceutical & biotech companies segment, which will gain $107.8 million of global annual sales by 2030. The ABSL-3 lab services market size will gain the most in the USA at $78.3 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the ABSL-3 (animal biosafety level 3) lab services companies to focus on expanding high-containment animal research capabilities, focus on multi-site infrastructure expansion and public sector partnerships, focus on expanding high-containment animal research capabilities, focus on regulatory alignment and certification readiness, focus on viral infections segment expansion, focus on expanding viral research services, expand in emerging markets, continue to focus on developed markets, focus on expanding and optimizing distribution networks, focus on structured value-based pricing with risk and compliance alignment, build authority through targeted educational promotion, strengthen credibility with proof and precision targeting and focus on skilled talent development and research-aligned engagement.